



# Johnson & Johnson (JNJ)

Updated July 17<sup>th</sup>, 2024 by Nathan Parsh

## Key Metrics

<b>Current Price:</b>	\$156	<b>5 Year CAGR Estimate:</b>	10.6%	<b>Market Cap:</b>	\$363 billion
<b>Fair Value Price:</b>	\$171	<b>5 Year Growth Estimate:</b>	6.0%	<b>Ex-Dividend Date:</b>	08/27/24
<b>% Fair Value:</b>	91%	<b>5 Year Valuation Multiple Estimate:</b>	1.8%	<b>Dividend Payment Date:</b>	09/10/24
<b>Dividend Yield:</b>	3.2%	<b>5 Year Price Target</b>	\$229	<b>Years Of Dividend Growth:</b>	62
<b>Dividend Risk Score:</b>	A	<b>Retirement Suitability Score:</b>	A	<b>Rating:</b>	Buy

## Overview & Current Events

Johnson & Johnson is a diversified health care company and a leader in the area of innovative medicines and medical devices Johnson & Johnson was founded in 1886 and employs nearly 132,000 people around the world. The company is projected to generate more than \$89 billion in revenue this year.

On May 4<sup>th</sup>, 2023, Kenvue, began trading on the New York Stock Exchange under the ticker symbol KVUE.

On April 16<sup>th</sup>, 2024, Johnson & Johnson announced that it was increasing its quarterly dividend 4.2% to \$1.24, extending the company's dividend growth streak to 62 consecutive years.

On May 31<sup>st</sup>, 2024, Johnson & Johnson completed its \$13.1 billion purchase of cardiovascular medical device company Shockwave Medical.

On July 17<sup>th</sup>, 2024, Johnson & Johnson announced second quarter results for the period ending June 30<sup>th</sup>, 2024. For the quarter, revenue grew 4.3% to \$22.4 billion, which was \$60 million more than expected. Adjusted earnings-per-share of \$2.82 compared to \$2.80 in the prior year and was \$0.12 ahead of estimates.

Excluding Covid-19 vaccine sales, the company's revenue total grew 7.1% in the second quarter. Revenue for Innovative Medicines improved 5.5% on a reported basis, but was higher by 8.8% when excluding currency translation. Infectious Disease fell 13% excluding currency, mostly due to reduced Covid-19 vaccine revenue, though the year-over-year declines are becoming less pronounced. Oncology continues to act well, with revenue up almost 19% due to continued strength in *Darzalex*, which treats multiple myeloma. *Imbruvica*, which treats lymphoma, still leads in market share, but continues to suffer declines due to competitive pressures. Immunology was up 7.3%. *Stelara*, which treats immune-mediated inflammatory diseases, once again benefited from market growth, but had an unfavorable patient mix during the quarter. Revenue for MedTech was up 2.2% on a reported basis and grew 4.4% excluding the impact of currency exchange. Cardiovascular continues to be the standout performer, as sales were up 18% due to gains in both global procedures and new products.

Johnson & Johnson offered revised guidance for 2024 as well. The company now expects revenue in a range of \$89.2 billion to \$89.6 billion, up from \$88.7 billion to \$89.1 billion and \$88.2 billion to \$89 billion previously. Adjusted earnings-per-share is now projected to be in a range of \$10.00 to \$10.10, down from \$10.60 to \$10.75 and \$10.55 to \$10.75 previously. The company's earnings forecast was adjusted to include the costs of acquisitions. We have updated our forecast accordingly.

## Growth on a Per-Share Basis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
<b>EPS</b>	\$5.70	\$5.48	\$5.93	\$7.30	\$8.18	\$8.68	\$8.03	\$9.80	\$10.15	\$9.92	<b>\$10.05</b>	<b>\$13.45</b>
<b>DPS</b>	\$2.76	\$2.95	\$3.15	\$3.32	\$3.54	\$3.80	\$4.04	\$4.19	\$4.45	\$4.70	<b>\$4.96</b>	<b>\$6.64</b>
<b>Shares<sup>1</sup></b>	2783	2755	2707	2683	2650	2684	2669	2670	2661	2431	<b>2422</b>	<b>2415</b>

<sup>1</sup> In millions of shares.

Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 17<sup>th</sup>, 2024 by Nathan Parsh

Johnson & Johnson has grown earnings over the past 10 years at a rate of 6.3%. The company managed to grow earnings before, during and after the last recession, showing that the company's products are in demand regardless of market conditions. We expect earnings-per-share to grow at a rate of 6% per year through 2029 due to gains in revenue, acquisitions, and share repurchases. This is consistent with Johnson & Johnson's earnings growth composition in the past, however, most growth will come from revenue expansion as the buyback is good for a low-single-digit share reduction annually.

## Valuation Analysis

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	Now	2029
Avg. P/E	17.7	18.2	19.1	23.9	23.7	15.6	18.2	17.5	17.4	15.8	15.5	17.0
Avg. Yld.	2.7%	3.0%	2.8%	2.6%	2.7%	2.6%	2.5%	2.5%	3.0%	3.1%	3.2%	2.9%

Shares of Johnson & Johnson have increased \$11, or 7.6%, since our April 16<sup>th</sup>, 2024 update. Using guidance for earnings-per-share for the year, Johnson & Johnson trades with a price-to-earnings ratio of 15.5, which is below our target price-to-earnings ratio of 17.0. Multiple expansion could add 1.8% to annual returns through 2029.

## Safety, Quality, Competitive Advantage, & Recession Resiliency


Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2029
Payout	48%	54%	53%	46%	43%	44%	50%	43%	44%	47%	49%	49%

Even after 60+ years of dividend growth, Johnson & Johnson has a reasonably low dividend payout ratio. This gives the company ample room to raise its dividend, even in a prolonged recession. One of Johnson & Johnson's key competitive advantages is the size and scale of its business. The company is a worldwide leader in a number of healthcare categories. Johnson & Johnson's diversification allows it to continue to grow even if one of the segments is underperforming. The recent separation of the consumer businesses should allow the company to unlock value for shareholders as the faster growing segments, Innovative Medicines and MedTech, could receive a higher multiple from the market.

## Final Thoughts & Recommendation

After second quarter earnings results, Johnson & Johnson is expected to offer a total annual return of 10.6% through 2029, down from our prior forecast of 13.5%. Our projected return stems from a 6% earnings growth rate, a starting yield of 3.2%, and a small contribution from multiple expansion. Johnson & Johnson continues to post solid results following the spinoff of its consumer business. Shares trade at a discounted valuation as well. We have lowered our five-year price target \$14 to \$229 due to revised guidance for 2024, but we continue to rate shares of Johnson & Johnson as a buy due to projected returns.

## Total Return Breakdown by Year



Disclosure: This analyst has a long position in the security discussed in this research report.



# Johnson & Johnson (JNJ)

Updated July 17<sup>th</sup>, 2024 by Nathan Parsh

## Income Statement Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Revenue</b>	74,331	70,074	71,890	76,450	81,581	82,059	82,584	93,775	94,943	85,159
<b>Gross Profit</b>	51,585	48,538	50,101	51,011	54,490	54,503	54,157	63,920	63,854	58,606
<b>Gross Margin</b>	69.4%	69.3%	69.7%	66.7%	66.8%	66.4%	65.6%	68.2%	67.3%	68.8%
<b>D&amp;A Exp.</b>	3,895	3,746	3,754	5,642	6,929	7,009	7,231	7,390	6,970	7,486
<b>Operating Profit</b>	21,137	18,289	20,891	18,897	21,175	20,970	19,733	23,647	23,703	22,009
<b>Operating Margin</b>	28.4%	26.1%	29.1%	24.7%	26.0%	25.6%	23.9%	25.2%	25.0%	25.8%
<b>Net Profit</b>	16,323	15,409	16,540	1,300	15,297	15,119	14,714	20,878	17,941	35,153
<b>Net Margin</b>	22.0%	22.0%	23.0%	1.7%	18.8%	18.4%	17.8%	22.3%	18.9%	41.3%
<b>Free Cash Flow</b>	14,996	16,106	15,541	17,777	18,531	19,918	20,189	19,758	17,185	17,778
<b>Income Tax</b>	4,240	3,787	3,263	16,373	2,702	2,209	1,783	1,898	3,784	1,736

## Balance Sheet Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Total Assets (\$B)</b>	130.4	133.4	141.2	157.3	153.0	157.7	174.9	182.0	187.4	167.6
<b>Cash &amp; Equivalents</b>	14,523	13,732	18,972	17,824	18,107	17,305	13,985	14,487	14,127	21,859
<b>Acc. Receivable</b>	10,985	10,734	11,699	13,490	14,098	14,481	13,576	15,283	16,160	14,873
<b>Inventories</b>	8,184	8,053	8,144	8,765	8,599	9,020	9,344	10,387	12,483	11,181
<b>Goodwill &amp; Int.</b>	49,054	47,393	49,681	85,134	78,064	81,282	89,795	81,638	93,556	70,733
<b>Total Liabilities</b>	60,606	62,261	70,790	97,143	93,202	98,257	111,616	107,995	110,574	98,784
<b>Accounts Payable</b>	7,633	6,668	6,918	7,310	7,537	8,544	9,505	11,055	11,703	9,632
<b>Long-Term Debt</b>	18,760	19,861	27,126	34,581	30,480	27,696	35,266	33,751	39,659	29,332
<b>Total Equity</b>	69,752	71,150	70,418	60,160	59,752	59,471	63,278	74,023	76,804	68,774
<b>LTD/E Ratio</b>	0.27	0.28	0.39	0.57	0.51	0.47	0.56	0.46	0.52	0.43

## Profitability & Per Share Metrics

Year	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023
<b>Return on Assets</b>	12.4%	11.7%	12.0%	0.9%	9.9%	9.7%	8.8%	11.7%	9.7%	19.8%
<b>Return on Equity</b>	22.7%	21.9%	23.4%	2.0%	25.5%	25.4%	24.0%	30.4%	23.8%	48.3%
<b>ROIC</b>	18.1%	17.2%	17.5%	1.4%	16.5%	17.0%	15.8%	20.2%	16.0%	32.8%
<b>Shares Out.</b>	2783	2755	2707	2683	2650	2684	2669	2667	2661	2560
<b>Revenue/Share</b>	25.95	24.91	25.78	27.85	29.90	30.57	30.92	35.07	35.64	33.26
<b>FCF/Share</b>	5.24	5.73	5.57	6.48	6.79	7.42	7.56	7.39	6.45	6.94

Note: All figures in millions of U.S. Dollars unless per share or indicated otherwise.

### Disclaimer

Nothing presented herein is, or is intended to constitute, specific investment advice. Nothing in this research report should be construed as a recommendation to follow any investment strategy or allocation. Any forward-looking statements or forecasts are based on assumptions and actual results are expected to vary from any such statements or forecasts. No reliance should be placed on any such statements or forecasts when making any investment decision. While Sure Dividend has used reasonable efforts to obtain information from reliable sources, we make no representations or warranties as to the accuracy, reliability or completeness of third-party information presented herein. No guarantee of investment performance is being provided and no inference to the contrary should be made. There is a risk of loss from an investment in marketable securities. Past performance is not a guarantee of future performance.